MariTide Research for Type 2 Diabetes
An evidence-based overview of research examining MariTide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
In the obesity-with-type-2-diabetes cohort of the published Phase 2 trial (NCT05669599; Jastreboff et al., NEJM 2025), maridebart cafraglutide produced up to -12.3% body weight at 52 weeks vs -1.7% with placebo, along with HbA1c reductions of 1.2 to 1.6 percentage points. The MARITIME-2 Phase 3 trial (NCT06858878) is evaluating efficacy in adults with type 2 diabetes and obesity or overweight; it is ongoing and has not yet reported.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. MariTide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.